Review: Pharmacotherapy for smoking cessation
Author(s) -
Laura Carrozzi,
Francesco Pistelli,
Giovanni Viegi
Publication year - 2008
Publication title -
therapeutic advances in respiratory disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.022
H-Index - 37
eISSN - 1753-4666
pISSN - 1753-4658
DOI - 10.1177/1753465808096136
Subject(s) - varenicline , medicine , pharmacotherapy , smoking cessation , nicotine replacement therapy , bupropion , intensive care medicine , psychiatry , pathology
Tobacco dependence is a chronic relapsing disease that needs continuous treatment. In combination with behavioural support, pharmacotherapy is a proven key component for supporting smoking cessation. Effective drugs are available and recommended: nicotine replacement therapy (NRT), bupropion and varenicline. Much research into new pharmacological approaches is ongoing, combining 'old' and 'new' drugs and personalizing a pharmacological treatment for a single smoker/patient; other new medications and vaccines are in development. Overall, pharmacotherapy seems to have efficacy and cost-effectiveness in real life, thus physicians should become familiar with these medicines. Further efforts should be aimed at optimizing treatment management and increasing smoking cessation rates in the general population.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom